Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8486410 | Vaccine | 2017 | 4 Pages |
Abstract
Q-Vax®, a whole cell formalin inactivated vaccine, is currently the only licensed Q fever vaccine for humans world-wide. Efficacy is high, although vaccine failures have been described for those vaccinated within the incubation of a naturally acquired infection. In Australia, it is widely used to prevent occupational acquisition of Q fever and is the mainstay for outbreak control. A retrospective review of all notified cases of acute Q fever to the Victorian department of health, 1993-2013, revealed 34 of 659 cases were previously vaccinated and 10 cases were positive on pre-vaccination screening, precluding vaccination. Twenty-one cases described high-risk exposures for C. burnetii prior to and within 15â¯days post vaccination and are likely to have been vaccinated within the incubation period of a natural infection. Thirteen cases described symptom onset more than 15â¯days post vaccination and thus may represent the first described series of Q-Vax vaccine failures following appropriate vaccination.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Katherine A. Bond, Lucinda J. Franklin, Brett Sutton, Simon M. Firestone,